Jafron Biomedical Co Ltd
SZSE:300529
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.6
37.82
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Jafron Biomedical Co Ltd
Total Equity
Jafron Biomedical Co Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
J
|
Jafron Biomedical Co Ltd
SZSE:300529
|
Total Equity
¥3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
A
|
APT Medical Inc
SSE:688617
|
Total Equity
¥1.9B
|
CAGR 3-Years
61%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
Total Equity
¥12.1B
|
CAGR 3-Years
14%
|
CAGR 5-Years
15%
|
CAGR 10-Years
22%
|
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
Total Equity
¥38.8B
|
CAGR 3-Years
17%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
L
|
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
|
Total Equity
¥15.9B
|
CAGR 3-Years
11%
|
CAGR 5-Years
16%
|
CAGR 10-Years
18%
|
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
Total Equity
¥18.9B
|
CAGR 3-Years
74%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Jafron Biomedical Co Ltd
Glance View
Jafron Biomedical Co., Ltd. engages in the research, development, production, and sale of hemoperfusion products. The company is headquartered in Zhuhai, Guangdong and currently employs 2,887 full-time employees. The company went IPO on 2016-08-02. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Company’s products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Company’s products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Company’s products are applied in 31 provinces, more than 3000 hospitals in China.
See Also
What is Jafron Biomedical Co Ltd's Total Equity?
Total Equity
3B
CNY
Based on the financial report for Jun 30, 2024, Jafron Biomedical Co Ltd's Total Equity amounts to 3B CNY.
What is Jafron Biomedical Co Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
10%
Over the last year, the Total Equity growth was -6%. The average annual Total Equity growth rates for Jafron Biomedical Co Ltd have been -2% over the past three years , 10% over the past five years .
You don't have any saved screeners yet
